Capricor Therapeutics Inc Stock
A very strong showing by Capricor Therapeutics Inc today, with an increase of €0.12 (3.450%) compared to yesterday's price.
Our community identified positive and negative aspects for Capricor Therapeutics Inc stock for the coming years. 0 users see the criterium "Return on equity" as a plus for the Capricor Therapeutics Inc stock. On the other hand our users think that "Return on equity" could be a problem in the future.
Pros and Cons of Capricor Therapeutics Inc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Capricor Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | 3.450% | -80.756% | -83.539% | -51.171% | -86.998% | -17.040% | -9.375% |
| Evolus Inc | -1.260% | -3.871% | -15.000% | -34.208% | -7.046% | -44.330% | -42.757% |
| Heron Therapeutics Inc. | 0.230% | 2.964% | 15.931% | -70.432% | -61.329% | -70.694% | -95.846% |
| Rhythm Pharmaceuticals | 0.000% | -5.000% | -11.856% | 14.765% | -8.556% | 437.736% | 493.750% |
News
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), reported the exercise of 24,100 stock options and immediate sale of the underlying common shares for a total transaction
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Key Points
- Interested in Capricor Therapeutics, Inc.? Here are five stocks we like better.
- Capricor Therapeutics says it is in active discussions with the FDA to support approval of deramiocel
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review